Pegylation improves the pharmacokinetics and bioavailability of small-molecule drugs hydrolyzable by esterases: A study of phospho-ibuprofen

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 1, 2014, Pages 61-66

  Mattheolabakis, George ^a   Wong, Chi C ^a   Sun, Yu ^a   Amella, Carol A ^a   Richards, Robert ^a   Constantinides, Panayiotis P ^b   Rigas, Basil ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b Medicon Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLESTERASE; CARBOXYLESTERASE 1; CARBOXYLESTERASE 2; IBUPROFEN; IBUPROFEN DERIVATIVE; MACROGOL 2000; PHOSPHOIBUPROFEN POLYETHYLENE GLYCOL; UNCLASSIFIED DRUG; 2-(4-ISOBUTYLPHENYL)PROPIONIC ACID 4-(DIETHOXYPHOSPHORYLOXY)BUTYL ESTER; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; MONOMETHOXYPOLYETHYLENE GLYCOL; ORGANOPHOSPHATE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CHEMOPROPHYLAXIS; COLON CANCER; CONTROLLED STUDY; COVALENT BOND; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TUMOR LEVEL; DRUG UPTAKE; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; COLONIC NEOPLASMS; DRUG SCREENING; GENETICS; HEK293 CELL LINE; HYDROLYSIS; METABOLISM; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOXYLIC ESTER HYDROLASES; CELL LINE, TUMOR; COLONIC NEOPLASMS; HEK293 CELLS; HUMANS; HYDROLYSIS; IBUPROFEN; MICE; ORGANOPHOSPHATES; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907180244     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.217208     Document Type: Article

References (14)

1. Choi JS and Jo BW (2004) Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int J Pharm 280: 221-227.
2. Greenwald RB, Choe YH, McGuire J, and Conover CD (2003) Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 55:217-250.
3. Harris JM and Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214-221.
4. Hong M, Zhu S, Jiang Y, Tang G, Sun C, Fang C, Shi B, and Pei Y (2010) Novel antitumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEGnanoparticles. J Control Release 141:22-29.
5. Hoofnagle JH and Seeff LB (2006) Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 355:2444-2451.
6. Johnson CC, Hayes RB, Schoen RE, Gunter MJ, and Huang WY; PLCO Trial Team (2010) Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial. Am J Gastroenterol 105:2646-2655.
7. Mattheolabakis G, Nie T, Constantinides PP, and Rigas B (2012a) Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC- 917): preparation, characterization, and in vitro/in vivo evaluation. Pharm Res 29: 1435-1443.
8. Mattheolabakis G, Rigas B, and Constantinides PP (2012b) Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine (Lond) 7:1577-1590.
9. Rainsford KD (1999) Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 107:27S-35S; discussion 35S-36S.
10. Scott LC, Yao JC, Benson AB, 3rd, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, and Ajani JA, et al. (2009) A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastrooesophageal junction adenocarcinoma. Cancer Chemother Pharmacol 63:363-370.
11. Sun Y, Rowehl LM, Huang L, Mackenzie GG, Vrankova K, Komninou D, and Rigas B (2012) Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system. Breast Cancer Res 14:R20.
12. Tirosh O, Kohen R, Katzhendler J, Gorodetsky R, and Barenholz Y (1997) Novel synthetic phospholipid protects lipid bilayers against oxidation damage: Role of hydration layer and bound water. J Chem Soc Perk T 2:383-389.
13. Wong CC, Cheng KW, Xie G, Zhou D, Zhu CH, Constantinides PP, and Rigas B (2012) Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity. J Pharmacol Exp Ther 340:422-432.
14. Xie G, Sun Y, Nie T, Mackenzie GG, Huang L, Kopelovich L, Komninou D, and Rigas B (2011) Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. J Pharmacol Exp Ther 337:876-886.